Demographic and clinical characteristics of CML patients in study cohorts 1 and 3 at study entry
| Patient characteristics, mean (SD) . | Cohort 1, n = 35 . | Cohort 3, n = 152 . | ||
|---|---|---|---|---|
| Age, y | 52.7 (13.8) | 51.1 (13.6) | ||
| Education level, y | 14.7 (1.90) | 14.7 (2.3) | ||
| Time since diagnosis, mo | 70.8 (64.8) | 72.5 (56.4) | ||
| Patient characteristics, no. (%) | ||||
| Sex | ||||
| Men | 16 (46) | 71 (47) | ||
| Women | 19 (54) | 81 (53) | ||
| Race and ethnicity | ||||
| Hispanic, black non-Hispanic, Asian, and Native American | 6 (17) | 37 (24) | ||
| White non-Hispanic | 29 (83) | 115 (76) | ||
| Marital status | ||||
| Married | 27 (77) | 115 (76) | ||
| Not married | 8 (23) | 37 (24) | ||
| Employment status | ||||
| Employed outside the home | 20 (57) | 91 (60) | ||
| Not employed | 15 (43) | 61 (40) | ||
| ECOG PS score | ||||
| Good (1 or lower) | 34 (97) | 149 (98) | ||
| Poor (2 or higher) | 1 (3) | 3 (2) | ||
| CML phase | ||||
| Chronic phase | 32 (91) | 148 (97) | ||
| Accelerated phase | 1 (3) | 1 (1) | ||
| Blast crisis | 2 (6) | 3 (2) | ||
| Disease response | ||||
| Hematologic | 34 (97) | 131 (86) | ||
| Complete cytogenetic | 26 (74) | 131 (86) | ||
| Complete or major molecular | 60 (21) | 53 (80) | ||
| Previous therapy | ||||
| Yes | 28 (80) | 116 (76) | ||
| No | 7 (20) | 36 (24) | ||
| Treatment | Previous | Current | Previous | Current |
| Imatinib | 23 (66) | 7 (20) | 57 (38) | 71 (47) |
| Dasatinib | 6 (17) | 16 (46) | 13 (9) | 34 (22) |
| Nilotinib | 4 (11) | 4 (11) | 9 (6) | 22 (14) |
| Bosutinib | 5 (14) | 1 (3) | 4 (3) | 6 (4) |
| Ponatinib | 0 | 3 (8) | 0 | 5 (3) |
| Bafetinib | 1 (3) | 1 (3) | 0 | 1 (1) |
| Rebastinib | 0 | 1 (3) | 0 | 3 (2) |
| Other drug therapy | 22 (63) | 1 (3) | 88 (58) | 3 (2) |
| HSCT in last 3 mo | 5 (14) | 0 (0) | 7 (5) | 1 (1) |
| No treatment | 0 | 1 (3) | 0 | 7 (5) |
| Patient characteristics, mean (SD) . | Cohort 1, n = 35 . | Cohort 3, n = 152 . | ||
|---|---|---|---|---|
| Age, y | 52.7 (13.8) | 51.1 (13.6) | ||
| Education level, y | 14.7 (1.90) | 14.7 (2.3) | ||
| Time since diagnosis, mo | 70.8 (64.8) | 72.5 (56.4) | ||
| Patient characteristics, no. (%) | ||||
| Sex | ||||
| Men | 16 (46) | 71 (47) | ||
| Women | 19 (54) | 81 (53) | ||
| Race and ethnicity | ||||
| Hispanic, black non-Hispanic, Asian, and Native American | 6 (17) | 37 (24) | ||
| White non-Hispanic | 29 (83) | 115 (76) | ||
| Marital status | ||||
| Married | 27 (77) | 115 (76) | ||
| Not married | 8 (23) | 37 (24) | ||
| Employment status | ||||
| Employed outside the home | 20 (57) | 91 (60) | ||
| Not employed | 15 (43) | 61 (40) | ||
| ECOG PS score | ||||
| Good (1 or lower) | 34 (97) | 149 (98) | ||
| Poor (2 or higher) | 1 (3) | 3 (2) | ||
| CML phase | ||||
| Chronic phase | 32 (91) | 148 (97) | ||
| Accelerated phase | 1 (3) | 1 (1) | ||
| Blast crisis | 2 (6) | 3 (2) | ||
| Disease response | ||||
| Hematologic | 34 (97) | 131 (86) | ||
| Complete cytogenetic | 26 (74) | 131 (86) | ||
| Complete or major molecular | 60 (21) | 53 (80) | ||
| Previous therapy | ||||
| Yes | 28 (80) | 116 (76) | ||
| No | 7 (20) | 36 (24) | ||
| Treatment | Previous | Current | Previous | Current |
| Imatinib | 23 (66) | 7 (20) | 57 (38) | 71 (47) |
| Dasatinib | 6 (17) | 16 (46) | 13 (9) | 34 (22) |
| Nilotinib | 4 (11) | 4 (11) | 9 (6) | 22 (14) |
| Bosutinib | 5 (14) | 1 (3) | 4 (3) | 6 (4) |
| Ponatinib | 0 | 3 (8) | 0 | 5 (3) |
| Bafetinib | 1 (3) | 1 (3) | 0 | 1 (1) |
| Rebastinib | 0 | 1 (3) | 0 | 3 (2) |
| Other drug therapy | 22 (63) | 1 (3) | 88 (58) | 3 (2) |
| HSCT in last 3 mo | 5 (14) | 0 (0) | 7 (5) | 1 (1) |
| No treatment | 0 | 1 (3) | 0 | 7 (5) |
HSCT, hematopoietic stem cell transplant.